Pleryon Therapeutics Limited
NovaMatrix develops novel controlled release therapeutics for eye diseases using its proprietary injectable hydrogel technology. Its products are biocompatible to the eye and work with existing protein based drug. The drug will be slowly released from the release depot to prolong the drug effect period from 2 to 4 weeks to over 6 to 12 months. Therefore the number of injection needed to achieve a therapeutic effect will be significantly reduced. It is biocompatible to eyes and works with existing protein based drugs.
1A No, 110 Ma Yau Tong Village Tsueng Kwan O, NT